Investing in Psychedelic BioTech [August 2025 webinar replay]
Human 3 with Brom and Sam30 Heinä 2025

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP



2025 has been the start of a bull period for psychedelic medicine.

​Psychedelic Biotechs like GH Research, Compass Pathways and Lykos Therapeutics are releasing impressive, late stage clinical trial data

​Capital is following the data: Cybin just raised $500M and Johnson and Johnson's Ketamine-inspired antidepressant Spravato broke $1B+ / year of topline.

​A new administration seems surprisingly interested in accelerating the FDA approval of psychedelics as treatments for mental health disorders

​Learn how top VCs and LPs are mapping and allocating to this exciting space in this special event designed for family offices and HNWIs.

​You will learn:

​The contrasting approaches that biotech and pharma are taking to commercialize psychedelic medicine

​Where we see the highest-leverage points for investing

​Lessons from past failures

​And of course there will be plenty of time for interaction and Q&A

​This event is run by Brom Rector and Sam Tabone of XEIA, a venture capital fund that invests in "Human 3 - the next epoch of human health, wellbeing and performance". As part of their Human 3 thesis, they have invested in 8 psychedelic medicine companies from pre-seed to pre-IPO.


Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(32)

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Elo 20251h 24min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Heinä 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Heinä 20251h 33min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Heinä 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Heinä 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Heinä 20251h

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

Arye Lipman is the cofounder of Biosphere, a startup that recently raised millions of dollars from Peter Thiel's Founders Fund and Chris Sacca's Lower Carbon Capital to Unleash Industrial Biomanufactu...

30 Kesä 20251h 20min